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The presented study aimed to elucidate the toxicokinetics of the four synthetic cathinones 4-
chloroethcathinone (4-CEC), N-ethylnorpentylone (N-ethylpentylone, ephylone), N-ethylhexedrone 
(NEH), and 4-fluoro-alpha-pyrrolidinohexiophenone (4-fluoro-alpha-pyrrolidinohexanophenone, 4-
F- -PHP, 4F-alpha-PHP, 4F-PHP). 
Methods  
First, their metabolism was studied using human urine and blood samples. Analysis of specimens 
was performed by liquid chromatography-high resolution tandem mass spectrometry (LC-
HRMS/MS) and gas chromatography-mass spectrometry (GC-MS). LC-HRMS/MS was also used 
to analyze in vitro incubations of the new psychoactive substances using pooled human liver S9 
fraction (pS9), to identify the monooxygenases involved in the initial metabolic steps, and 
determination of plasma concentrations after standard addition method. Metabolic stability was 
tested in pooled human liver microsomes incubations analyzed by LC-ion trap MS. 
Results  
Using LC-HRMS/MS, in total 47 metabolites were found in patient samples and pS9 incubations. 
Using GC-MS, 4-CEC, ephylone, NEH, and five of their metabolites were detectable in urine. The 
following main phase I reactions were observed: carbonyl group reduction, N-deethylation, 
hydroxylation, lactam formation (4F-PHP), and demethylenation (ephylone). Mainly 
glucuronidations were observed as phase II reactions besides conjugates with the dicarboxylic acids 
malonic, succinic, and glutaric acid (4-CEC), sulfation, methylation (both ephylone), and N-
acetylation (NEH). A broad range of monooxygenases was involved in the initial steps with 
exception of NEH (only CYP1A2 and CYP2C19). 4F-PHP had the shortest in vitro half-life (38 
min) and highest intrinsic clearance (15.7 mL×min-1×kg-1). Plasma concentrations ranged from 0.8 
to 8.5 ng/mL. 
Conclusions 




suspected abuse and allow them a thorough risk assessment. 
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The global new psychoactive substances (NPS) market is still characterized by the emergence of 
large numbers of new substances belonging to diverse chemical groups. Synthetic cathinones 
represent one of the largest groups and are frequently reported to the United Nations Office on 
Drugs and Crime (UNODC) [1]. Synthetic cathinones are chemically related to cathinone, which is 
a naturally occurring stimulant found in the khat plant (Catha edulis), and their pharmacodynamic 
profile is similar to that of other psychomotor stimulants including amphetamine-like monoamine 
releasing properties or cocaine-like blockade of monoamine reuptake [2, 3]. As most synthetic 
cathinones are sold as "legal highs" and not internationally controlled, they represent an ongoing 
issue for clinical and forensic toxicologists who must identify an unending variety of new drugs of 
abuse [4]. The knowledge about the toxicokinetics of NPS is essential for analytics but also for 
thorough risk assessment particularly if compounds are co-ingested with other NPS and/or 
therapeutics. In terms of cathinone abuse, the parent compound is often detectable in human 
specimens including urine [3], but identification of metabolites may confirm a positive screening 
result or allow a detection in late excretion phases.  
The current study was based on specimens collected from a 41-year-old male who was 
admitted to the hospital displaying uncontrolled movements and aggressive behavior. The 
toxicological screening detected four synthetic cathinones (see Figure 1), by name 4-
chloroethcathinone (4-CEC), N-ethylnorpentylone (N-ethylpentylone, ephylone), N-ethylhexedrone 
(NEH), and 4-fluoro-alpha-pyrrolidinohexiophenone (4-fluoro-alpha-pyrrolidinohexanophenone, 4-
F- -PHP, 4F-alpha-PHP, 4F-PHP) in blood and urine samples. The patient was discharged from 
hospital the next day due to an uneventful course. No metabolites of the detected NPS were 
described yet, with exception of four ephylone phase I metabolites detected in incubations with 
human liver microsomes (HLM) [5]. The rationale and aim of the present study was therefore to 
identify metabolites in patient specimens using liquid chromatography coupled to high-resolution 
tandem mass spectrometry (LC-HRMS/MS) and gas chromatography-mass spectrometry (GC-MS). 




using pooled human liver S9 fraction (pS9). Based on these data suitable analytical targets should 
be recommended. The monooxygenases involved in the initial metabolic steps should be identified, 
plasma concentrations determined, and a metabolic stability study in pooled HLM (pHLM) 
conducted to expand the knowledge surrounding these synthetic cathinones' toxicokinetics. 
 
Materials and methods 
Chemicals and enzymes 
4-CEC, ephylone, NEH, and 4F-PHP were obtained from an online vendor of NPS based in the 
Netherlands and identity as well as purity confirmed by HPLC, IR, and MS/MS. Stock solutions of 
the synthetic cathinones were prepared in methanol (1 mg/mL, each) and stored at -20°C until use. 
Trimipramine‐d3 was from LGC (Wesel, Germany), NADP+ from Biomol (Hamburg, Germany), 
isocitrate, isocitrate deh drogenase, supero ide dismutase, 3 ‐phosphoadenosine‐5 ‐phosphosulfate 
(PAPS), S‐(5 ‐adenosyl)‐L-methionine (SAM), dithiothreitol (DTT), reduced glutathione (GSH), 
acetyl coenzyme A (AcCoA), magnesium chloride (MgCl2), potassium dihydrogenphosphate, 
dipotassium hydrogenphosphate, and Tris hydrochloride from Sigma‐Aldrich (Taufkirchen, 
Germany). Zinc sulfate heptahydrate, acetonitrile (LC-MS grade), ammonium formate (analytical 
grade), formic acid (LC-MS grade), methanol (LC-MS grade), and all other chemicals and reagents 
(analytical grade) were obtained from VWR (Darmstadt, Germany). The baculovirus-infected insect 
cell microsomes (Supersomes) containing 1 nmol/mL of human cDNA-expressed CYP1A2, 
CYP2A6, CYP2B6, CYP2C8, CYP2C9 (2 nmol/mL), CYP2C19, CYP2D6, CYP2E1 (2 nmol/mL), 
CYP3A4, CYP3A5 (2 nmol/mL), or FMO3 (5 mg protein/mL), and pHLM (20 mg microsomal 
protein/mL, 360 pmol total CYP/mg protein, 26 individual donors), pS9 (20 mg microsomal 
protein/mL, 25 individual donors), UGT reaction mixture solution A (25 mM UDP-glucuronic 
acid), and UGT reaction mixture solution B (250 mM Tris HCl, 40 mM MgCl2, and 125 µg/mL 




enzyme preparations were thawed at 37°C, aliquoted, snap‐frozen in liquid nitrogen, and stored at 
80 C until use.  
 
Preparation of human biosamples 
Authentic heparinized human blood plasma and human urine samples after suggested intake of 
drugs of abuse were submitted for clinical toxicological analysis to the authors' laboratory. The 
blood sample was centrifuged and plasma was separated. Plasma and urine were kept frozen 
( 20 C) until anal sis. Human plasma (250 µL) was prepared according to Helfer et al. by 
precipitation with 750 µL of a zinc sulfate solution (35 mg/mL in water:methanol, 70:30, v/v) [6]. 
After shaking and centrifugation (18,407 x g, 2 min), the supernatant was transferred into an LC 
vial and injected onto the LC-HRMS/MS system. Human urine (100 µL) was prepared according to 
Wissenbach et al. by precipitation with 500 µL of acetonitrile [7]. After shaking and centrifugation 
(18,407 x g, 2 min), the supernatant was transferred into a glass vial and evaporated to dryness 
under a gentle stream of nitrogen at 50°C. The residue was dissolved in 50 L of a mixture of 
eluent A and B (for LC-HRMS/MS, see chapter 2.7, 1:1, v/v), transferred into an LC vial, and 
injected onto the LC-HRMS/MS system. For analysis by GC-MS, the authors' standard liquid-
liquid extraction for plasma and systematic toxicological analysis procedure for urine, consisting of 
hydrolysis, extraction, and microwave-assisted acetylation was used, and GC-MS standard 
operation conditions [8]. Briefly, a Hewlett Packard (HP, Agilent Technologies, Waldbronn, 
Germany) 5890 Series II gas chromatograph, an HP 5970 MSD mass spectrometer, a cross-linked 
methylsilicone capillary Optima-5 MS (12 m×0.2 mm I.D.), film thickness 0.35 µm (Macherey-
Nagel, Düren, Germany) and the following conditions were used: injector port temperature, 280 °C; 
carrier gas, helium; flow rate 1 ml/min; column temperature, programmed from 100 to 310 °C at 
30°/min, initial time 3 min, final time 5 min; electron ionization (EI) mode, ionization energy, 70 
eV; ion source temperature, 200 °C; and scan rate, 1 scan/sec. 
 




As previously described by Richter et al. [9], the final incubation volume was 150 µL. Incubations 
were performed using pS9 (2 mg microsomal protein/mL) after preincubation for 10 min at 37 °C 
with 25 µg/mL alamethicin (UGT reaction mixture solution B), 90 mM phosphate buffer (pH 7.4), 
2.5 mM Mg2+, 2.5 mM isocitrate, 0.6 mM NADP+, 0.8 U/mL isocitrate dehydrogenase, 100 U/mL 
superoxide dismutase, and 0.1 mM AcCoA. Thereafter, 2.5 mM UDP-glucuronic acid (UGT 
reaction mixture solution A), 40 µM PAPS, 1.2 mM SAM, 1 mM DTT, 10 mM GSH, and 25 µM 
substrate (one of the four synthetic cathinones) were added. All given concentrations correspond to 
the final concentrations in one reaction tube. The organic solvent content in the final incubation 
mixtures was always below 1% [10]. The reaction was initiated by addition of the substrate and the 
reaction mixture was incubated for a maximum of 360 min. After 60 min, an aliquot of 60 µL of the 
incubation mixture was transferred to a reaction tube containing 20 µL ice-cold acetonitrile for 
termination of the reactions. The remaining mixture was incubated for additional 300 min and 
thereafter stopped by addition of 30 µL ice-cold acetonitrile. After addition of acetonitrile, mixtures 
were cooled for 30 min at -20°C, centrifuged (18,407 x g, 2 min), and supernatants transferred into 
LC vials, followed by injection onto the LC-HRMS/MS system. Blank samples without substrate 
and control samples without pS9 were prepared to confirm the absence of interfering compounds 
and identification of compounds not formed by metabolism, respectively. All incubations were 
performed in duplicate (n = 2). 
 
Monooxygenases activity screening  
According to a published procedure [11], microsomal incubations in duplicate were performed at 
37 °C for 30 min using a substrate concentration of 25 µM and CYP1A2, CYP2A6, CYP2B6, 
CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5 (75 pmol/mL each), or 
FMO3 (0.25 mg protein/mL). Reference incubations with pHLM (1 mg microsomal protein/mL) 
were used as positive control. Control samples without enzymes were prepared to assess formation 
of compounds not originated from metabolism. Besides enzymes and substrates, the incubation 




isocitrate, 1.2 mM NADP+, 0.5 U/mL isocitrate dehydrogenase, and 200 U/mL superoxide 
dismutase. For incubations with CYP2A6 or CYP2C9, phosphate buffer was replaced with 90 mM 
Tris buffer, respectivel , according to the manufacturer s recommendation. Reactions ere initiated 
by addition of the enzyme preparation and terminated by addition of 50 µL of ice-cold acetonitrile. 
Mixtures were centrifuged (18,407 x g, 2 min), supernatants transferred into LC vials, and injected 
onto the LC-HRMS/MS system.  
 
Determination of plasma concentrations 
Standard addition method was used for quantification of 4-CEC, ephylone, NEH, and 4F-PHP in 
the authentic human plasma sample. Briefly, 50 µL blood plasma were precipitated with 100 µL 
acetonitrile containing 0.1% formic acid. Additionally, five samples were prepared using 
acetonitrile containing the four synthetic cathinones resulting in final plasma concentrations of 2, 4, 
6, 8, and 10 g/L, respectively. Ten L of trimipramine‐d3 in methanol (2 g/L final plasma 
concentration) were added as internal standard. After shaking and centrifugation (-10°C, 
21,130 x g, 30 min), the supernatant was transferred into an LC vial and injected onto the LC-
HRMS/MS system. For quantification, the ratios of the corresponding peak area of analyte and 
internal standard in the HR full scan were used. 
 
Metabolic stability studies  
Metabolic stability incubations were performed with pHLM in accordance to chapter 2.4 with the 
following variations: 2.5 M substrate concentrations were used and incubations stopped after 0, 
30, 60, 90, 120, 150, and 180 min (4-CEC, ephylone, NEH) or 0, 15, 30, 45, 60, 75, and 90 min 
(4F-PHP) incubation time by addition of 50 µL of ice-cold acetonitrile containing 1 µM 
trimipramine‐d3 as internal standard. Additionally, control incubations (n = 2) without pHLM were 
prepared to assess degradation of parent compounds not originated from metabolism and stopped 
after 180 min (4-CEC, ephylone, NEH) or 90 min (4F-PHP). All incubations were performed in 




and injected onto the LC-ion trap (IT) MS system. The natural logarithm of the ratios of the 
corresponding peak area of analyte and internal standard in the HR full scan were used to assess 
degradation of parent compounds. GraphPad Prism 5.00 (GraphPad Software, San Diego, USA) 
was used for statistical evaluation. A t-test was used to determine whether ln[peak area ratio]initial 
values were significantly different from ln[peak area ratio] values in control incubations without 
pHLM using the following settings: unpaired; two-tailed; significance level, 0.05; confidence 
intervals, 99%. 
According to Baranczewski et al. [12], the following equations were used for calculations:  
(1) ln[peak area ratio]remaining = ln[peak area ratio]initial  k × t       and       t1/2 =  





(3) CLint = CLint, micr (  )× 
r
 
 × SF ( ) 
with k = slope of the linear regression fit, t1/2 = in vitro half-life, CLint, micr = microsomal intrinsic 
clearance, CLint = intrinsic clearance, [V]incubation = incubation volume = 0.05, [P]incubation = 
microsomal protein amount in the incubation = 0.05, r  = liver weight normalized by body 
weight [13] = 26, and SF = scaling factor microsomal protein per gram of liver [12] = 33. 
 
LC-HRMS/MS conditions 
A Thermo Fisher Scientific (TF, Dreieich, Germany) Dionex UltiMate 3000 Rapid Separation (RS) 
UHPLC system with a quaternary UltiMate 3000 RS pump and an HTC PAL autosampler was used 
and controlled by the Aria MX software. The chromatographic system was coupled to a TF Q-
Exactive Focus equipped with a heated electrospray ionization II (HESI-II) source. Injection 
volume was 10 µL for all samples. LC and MS conditions were in accordance to Michely et al. [14] 
with minor modifications. Gradient elution was performed using a TF Accucore PhenylHexyl 
column (100 mm x 2.1 mm inner diameter, 2.6 m particle size) at 35°C. The mobile phases 




and 2 mM ammonium formate in acetonitrile/methanol (50:50, v/v) containing formic acid (0.1%, 
v/v) and water (1%, v/v, eluent B). The gradient was programmed as follows: 0－1 min 1% B, 
1－10 min to 99% B, 10－11.5 min hold 99% B, and 11.5－13.5 min hold 1% B, at a flow rate of 
0.5 mL/min from 0 to 10 min and 0.8 mL/min from 10 to 13.5 min. The HESI‐II source conditions 
were as follows: heater temperature, 320°C; ion transfer capillary temperature, 320°C; sheath gas, 
60 arbitrary units (AU); auxiliary gas, 40 AU; spray voltage, 4.00 kV, and S-lens RF level, 50.0. 
Mass spectrometric analysis was performed in positive full scan mode and subsequent 
data‐dependent acquisition (DDA) with priority to mass‐to‐charge ratios (m/z) of parent compounds 
and their expected metabolites (separate inclusion lists for 4-CEC, ephylone, NEH, and 4F-PHP). 
Discovery mode was chosen to ensure the recording of MS2 spectra of precursor ions not in the 
inclusion list. The settings for full scan data acquisition were as follows: polarity, positive; 
resolution, 35,000; scan range, m/z 100－500; automatic gain control (AGC) target, 1e6; maximum 
injection time (IT), 120 ms; microscans, 1; spectrum data type, profile. The settings for the DDA 
mode were as follows: dd‐MS2, discovery; resolution, 17,500; isolation window, 1.0 m/z; AGC 
target, 2e5; maximum IT, 250 ms; high collision dissociation cell with stepped normalized collision 
energy, 17.5, 35.0, 52.5; loop count, 3; minimum AGC target, 2.5e3 (corresponds to a signal 
intensity threshold of 1.0e4); exclude isotopes, on; and spectrum data type, profile. Mass calibration 
was performed prior to analysis according to the manufacturer s recommendations using e ternal 
mass calibration. TF Xcalibur Qual Browser 4.0 software was used for data handling. The settings 
for automated peak integration were as follows: peak detection algorithm, ICIS; baseline window, 
40; area noise factor, 5; and peak noise factor, 10.  
 
LC-ITMS conditions 
A TF LXQ linear ion trap mass spectrometer equipped with a HESI‐II source and coupled to a TF 
Accela ultra HPLC (UHPLC) system consisting of a degasser, a quaternary pump, and an 




accordance to Wissenbach et al. with minor modifications [7]. Gradient elution was performed on a 
TF Hypersil GOLD C18 column (100×2.1 mm, 1.9 m) using 10 mM aqueous ammonium formate 
plus 0.1% formic acid pH 3.4 (eluent A) and acetonitrile plus 0.1% formic acid (eluent B). The flow 
rate was set to 0.5 mL/min, and the gradient was programmed as follows: 0 1.0 min 2% B, 1.0 3.0 
min to 10% B, 3.0 5.0 min to 15% B, 5.0 7.5 min to 20% B, 7.5 10.0 min to 25% B, 10.0 11.5 
min to 30% B, 11.5 13.0 min to 35% B, 13.0 14.5 min to 50% B, 14.5 16.0 min to 60% B, 16.0
19.0 min to 90% B, and 19.0 21.0 hold 90% B followed by column flushing and reequilibration. 
The injection volume for all samples was 10 L each. The MS conditions were as follows: polarity, 
positive; sheath gas, nitrogen at flow rate of 34 AU; auxiliary gas, nitrogen at flow rate of 11 AU; 
vaporizer temperature, 250 °C; source voltage, 3.00 kV; ion transfer capillary temperature, 300 °C; 
capillary voltage, 38 V; and tube lens voltage, 110 V. AGC was set to 15,000 ions for full scan and 
5,000 ions for MSn. The maximum IT for full scan (MS1 stage) was set to 100 ms, spectrum data 
type, profile. Collision-induced dissociation (CID)-MSn experiments were performed on precursor 
ions selected from MS1 using DDA: MS1 was performed in the full scan mode (m/z 100 800). MS2 
and MS3 were performed in the DDA mode: four DDA MS2 scan filters were chosen to provide 
MS2 on the four most intense signals from MS1, and additionally, eight MS3 scan filters were 
chosen to record MS3 on the most and second most intense signals from the MS2. MS2 spectra were 
collected with a higher priority than MS3 spectra. Normalized wideband collision energies were 
35.0% for MS2 and 40.0% for MS3. Other settings were as follows for MS2: minimum signal 
threshold, 100 counts; isolation width, 1.5 u; for MS3: minimum signal threshold, 50 counts; 
isolation width, 2.0 u; for both stages: activation Q, 0.25; activation time, 30 ms; and dynamic 
exclusion mode: repeat count, 2; repeat duration, 15 s; exclusion list size, 50; exclusion duration, 15 
s. 
 
Results and discussion 




The phase I and II metabolites of 4-CEC, ephylone, NEH, and 4F-PHP identified in authentic 
human biosamples or pS9 incubations by means of LC-HRMS/MS are summarized in the 
Electronic Supplementary Material (ESM) in Table S1. The information whether a metabolite was 
detected in plasma, urine and/or the in vitro incubations can be taken from Table S2 (ESM). The 
precursor ion (PI) mass recorded in MS1, characteristic fragment ions (FI) in MS2, relative 
intensities in MS2, calculated exact masses, elemental compositions, deviation of the measured 
from the calculated masses, and retention times (RT) are also given. Metabolites were sorted by 
increasing mass and RT and assigned to a unique Metabolite ID. In total, nine metabolites of 4-
CEC, 17 of ephylone, 11 of NEH, and 10 of 4F-PHP were tentatively identified. Furthermore, four 
pairs of diastereomers were identified (M12/13, M18/19, M37/38, M48/49). Absolute peak areas of 
4-CEC, ephylone, NEH, 4F-PHP, and their phase I and II metabolites in MS1 (positive ionization 
mode, ESI +) derived from analyses of authentic human biosamples and pS9 incubations by LC-
HRMS/MS are summarized in Table S2 (ESM). Parent compounds or metabolites identified in 
authentic human urine by means of GC-MS are given in Table S3 (ESM). Neither parent compound 
nor metabolites were detectable in the plasma sample by GC-MS. 
Because the number of NPS is constantly increasing, rapid and cost-effective methods are 
needed to study the metabolism of these compounds in order to develop suitable toxicological 
screening procedures. In vitro studies for example based on pS9 incubations provide a rapid way of 
generating an overview of the metabolic pathways [3, 15, 9, 16]. The presence of these preliminary 
metabolites should further be confirmed in vivo. For this purpose, animal models such as rats, pigs, 
or zebrafish larvae can be used, but species differences have to be considered [17-19]. An intake by 
humans in the framework of a controlled trial would be the gold standard, but is considered as 
unethical, time-consuming, and expensive. However, in rare cases, human biosamples after intake 
of NPS derived from authentic cases are available as presented in this study. These specimens were 
kept frozen until analysis as lowered temperature was shown to enhance stability of cathinones in 
blood samples [20]. MS-based procedures proved to be suitable for metabolism studies due to high 




of unknown compounds [21], but rather expensive and not available in every toxicological 
laboratory. Therefore, the detectability of the four synthetic cathinones and/or their metabolites in 
human biosamples by GC-MS was also investigated. For all compounds, LC-HRMS1 data was 
screened for potential exact PI masses of expected metabolites in the first step. Afterwards, the 
fragmentation pattern in the MS2 spectrum was interpreted and compared to that of the parent 
compound for tentative identification. Due to the high number of metabolites, the fragmentation 
patterns could not be discussed in detail for all metabolites and only the typical FI used for 
identification will be discussed. Only the calculated exact masses will be used in this chapter. 
As described by Niessen and Correa [22], loss of water (-18.0106 u, H2O) is characteristic for 
the fragmentation pattern of cathinones, but not pyrrolidinophenones. The spectra of 4-CEC, 
ephylone, NEH, and most of their metabolites contained intense FI after initial water loss, while the 
4F-PHP spectrum did not contain such a FI as given in Table S1 (ESM). In case of 4-CEC (PI at 
m/z 212.0837, C11H15ONCl), loss of water resulted in the FI at m/z 194.0731 (C11H13NCl) and the 
most intense FI at m/z 159.1043 was formed after subsequent loss of a chlorine radical (-34.9688). 
Both FI were shifted by -28.0313 u (C2H4) in the N-deethyl 4-CEC (M1) spectrum. After reduction 
of the carbonyl group (M3), water loss resulted in the most intense FI at m/z 196.0888. Due to the 
used HR device, the PI mass of M3 (m/z 214.0993) could be distinguished from the 2C13 isotope 
(m/z 214.0903) and the Cl37 isotope (m/z 214.0807) of 4-CEC. M3 was also detected as glucuronide 
(M9). Furthermore, conjugates of M1 and dicarboxylic acids, by name malonic acid, succinic acid, 
and glutaric acid, could be detected (M6-8). Analysis in negative ionization mode confirmed these 
findings (see ESM, Table S1). In rat urine, conjugates of mephedrone and methylone metabolites 
with succinic, glutaric, and adipic acid were previously detected [23, 24]. Nor-mephedrone 
succinate was also described to be present in human plasma and urine [25, 26]. However, to our 
knowledge, this is the first report of a synthetic cathinone metabolite bound to malonic acid and the 
first detection of a synthetic cathinone metabolite conjugate with glutaric acid in human urine. No 




Seventeen ephylone metabolites were detected, including the four phase I metabolites 
previously described by Krotulski et al. [5] . However, abundances of the metabolites (see ESM, 
Table S2) underline the importance of the additional identification of phase II metabolites. Eleven 
NEH metabolites could be identified including the only N-acetyl metabolite in this study, N-deethyl 
N-acetyl NEH (M32) and 10 4F-PHP metabolites were detected. All in all, metabolic pathways 
were comparable to the ones described for other synthetic cathinones [4].  
Four pairs of diastereomers were identified. The reduction of the carbonyl group formed two 
diastereomeric alcohols. Mass spectra within each pair of diastereomers were very similar as 
already described by Uralets et al. for other diastereomers of reduced cathinones [27]. Not always 
after carbonyl reduction, two diastereomers could be detected. Possible explanations could be an 
insufficient separation by the used LC system or stereospecific formation in varying quantities. 
4-CEC, ephylone, NEH, and five metabolites were detectable in the urine sample by GC-MS 
(see ESM, Table S3). The low number of detected metabolites and the negative screening result in 
plasma was potentially caused by insufficient volatility or quantity of the analytes and sensitivity of 
the used GC-MS apparatus. 
In order to identify suitable screening targets, absolute peak areas of 4-CEC, ephylone, NEH, 
4F-PHP, and their phase I and II metabolites derived from LC-HRMS/MS analyses of authentic 
human biosamples and pS9 incubations are given in Table S2 (ESM). Targets detected by GC-MS 
are given in Table S3 (ESM). For all four synthetic cathinones, the parent compound was amongst 
the most abundant signals in plasma and/or urine and should therefore be included in the screening 
procedure. For 4-CEC, the dihydro metabolite (M3), also in combination with N-deethylation (M2), 
could be recommended as additional target for LC-, and the corresponding acetylated metabolites 
for GC-based screening approaches. If no conjugate cleavage is performed during sample 
preparation, demethylenyl ephylone glucuronide (M26), with or without methylation (M27/28), 
should be considered for LC-based screening, otherwise the corresponding aglyca (M15-17), also 
for GC-MS as acetylated compounds. Only the parent compound NEH was detectable in urine by 




targets for LC-based screenings should be N-deethyl and hydroxy NEH (M29 and M33), as well as 
oxo 4F-PHP (M43 and M44). With exception of M43, all of these recommended targets were also 
detectable in the pS9 incubations and structures are given in Figure 2. As given in Table S2, a lower 
number of metabolites were detected in pS9 incubations in comparison to human biosamples. This 
was most probably caused by the lack of distribution and elimination processes in in vitro models, 
which could also lead to minor formation of metabolites in concentrations under the detection limit. 
Furthermore, pS9 was incubated for a maximum of 360 min, while time between intake and 
sampling of blood and urine may have been longer. Nevertheless, these findings are based on only 
one authentic case and should be considered as possible limitation. 
 
Involvement of monooxygenases in phase I metabolic reactions 
In order to identify the monooxygenases involved in the synthetic cathinones' phase I metabolic 
transformations, a monooxygenases activity screening was conducted consisting of incubations 
with one out of the ten most abundant CYP isoforms in human liver or FMO3. Incubations with 
pHLM were used as positive control to confirm suitable incubation conditions by metabolite 
formation. Results are summarized in Table 1. In case of all four synthetic cathinones, the dihydro 
metabolites (M3, M18, M31, M42) were only detected in pHLM incubations, but not in incubations 
with the recombinant monooxygenases. Therefore, the monooxygenase isoforms tested in this 
monooxygenases activity screening are not expected to catalyze the formation of the dihydro 
metabolites of 4-CEC, ephylone, NEH, and 4F-PHP. CYP2C19 was found to be involved in the 
formation of the N-deethyl metabolites of 4-CEC, ephylone, and NEH (M1, M10, M29), as well as 
in the N,N-dealkyl metabolite formation of 4F-PHP (M41). Depending on the synthetic cathinone, 
CYP1A2, CYP2B6, or CYP3A4 were also involved in the N-deethylation or N,N-dealkylation. 
Hydroxylamines were only detectable in incubations with 4-CEC (M4) and ephylone (M21) and 
their formation was catalyzed by CYP1A2 (only 4-CEC), CYP3A4, and FMO3. The formation of 
demethylenyl ephylone (M15) was catalyzed by CYP1A2, CYP2C19, and CYP2D6 and of hydroxy 




CYP1A2 incubations. CYP1A2 also catalyzed the formation of two hydroxy 4F-PHP isomers, 
while CYP2C19 and CYP3A4 formed all three isomers (M45-46). Oxo 4F-PHP (M44) was formed 
in incubations with CYP1A2, CYP2B6, and CYP3A4. 
In case of 4-CEC, ephylone, and 4F-PHP, at least four different monooxygenase isoforms 
were involved in the phase I metabolic transformations. Therefore, an inhibition of a single isoform 
in case of a drug-drug interaction or interindividual expression differences are not expected to have 
a significant influence on their concentrations, in contrast to NEH, where only two CYP isoforms 
were found to be involved in the phase I metabolic reactions. Especially an inhibition of CYP1A2 
would lead to almost complete inhibition of initial metabolic steps and could therefore cause a 
significant increase in NEH levels and toxicity.  
 
Determination of plasma concentrations 
Standard addition method was used and the authentic plasma sample analyzed without or with 
addition of the four synthetic cathinones resulting in final plasma concentrations of additionally 2, 
4, 6, 8, and 10 ng/mL respectively. In Figure 3, the analyte concentration is plotted versus the peak 
area ratio of analyte and internal standard. The data points on the y-axis represent the analyte 
amount in the native plasma sample and after linear regression, the following plasma concentrations 
were determined: 1.9 ng/mL 4-CEC, 8.5 ng/mL ephylone, 1.0 ng/mL NEH, and 0.8 ng/mL 4F-PHP. 
Unfortunately, dosage and time of intake were unknown. No plasma concentrations were published 
for 4-CEC, NEH, and 4F-PHP, so far. Published ephylone concentrations in toxicological death 
investigations and drugged driving casework ranged from 12 to 1,200 ng/mL [5]. Therefore, plasma 
concentrations determined in the presented case can be considered as low. This assumption was 
confirmed by the patient's health status including hospital discharge after one only day and 
comparison to published concentrations of other synthetic cathinones [4].  
 
 




Metabolic stability in pHLM incubations is depicted in Figure 4 and in vitro half-life (t1/2) values, 
calculated microsomal intrinsic clearances (CLint,micr), and intrinsic clearances (CLint) are 
summarized in Table 2. The shortest t1/2 was determined for 4F-PHP with 38 min. The other 
compounds provided t1/2 between 85 and 105 min. The highest CLint of 15.7 mL× min-1×kg-1 was 
determined for 4F-PHP, other CLint were between 5.7 and 7.0 mL× min-1×kg-1. 
Metabolic stability was determined based on disappearance of the test compound during 
incubation with pHLM and expressed as t1/2, CLint,micr, and CLint. The latter was calculated by 
scaling CLint,micr to whole liver dimensions. CLint is defined as the maximum activity of the liver 
towards a drug in the absence of other physiological determinants such as hepatic blood flow and 
drug binding within the blood matrix [12]. In general, the protein concentrations should be 
minimized to ensure the absence of non-specific protein binding and the concentration of a test 
compound during the incubation should be below the Michaelis-Menten constant (Km). As there 
was no information on Km values for the tested cathinones available, a preferably low concentration 
was used in the assay as recommended by Baranczewski et al. [12]. Non-metabolic degradation of 
the synthetic cathinones could be excluded by control incubations without pHLM and subsequent t-
tests that did not show a significant difference in the natural logarithms of the peak area ratios of 
incubations after 0 min and control incubations.  
According to McNaney et al. [28], 4F-PHP could be classified as intermediate clearance 
compound and 4-CEC, ephylone, and NEH as low clearance compounds. The determined values 
were comparable to the ones published for PV8 and 4-methoxy- -PVP [29, 30]. However, CLint of 
synthetic cathinones were much lower than the ones determined for synthetic cannabinoid receptor 
agonists [31, 32]. 
 
Conclusions 
In total, 47 metabolites of 4-CEC, ephylone, NEH, and 4F-PHP were identified in human 
biosamples and pS9 incubations including conjugates with dicarboxylic acids that were not 




procedures were recommended. As various monooxygenases were shown to be involved in the 
initial metabolic steps, interactions with other drugs (of abuse) based on enzyme inhibition should 
be unlikely, except for NEH where only CYP1A2 and CYP2C19 were involved. Due to the health 
status of the patient, the determined plasma concentrations between 0.8 and 8.5 ng/mL are expected 
to be rather low and not life-threatening. In vitro half-life values and intrinsic clearances indicated 
that these synthetic cathinones can be classified as intermediate (4F-PHP) or low (4-CEC, 
ephylone, and NEH) clearance compounds, comparable to other synthetic cathinones' clearances. In 
summary, the present work clearly expanded the knowledge about the toxicokinetics of the four 
synthetic cathinones and may help clinical and forensic toxicologists to reliably detect these 
compounds in human biosamples and interpret their findings. 
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Legends to the figures 
 
Figure 1. Chemical structures of the investigated synthetic cathinones. 
Figure 2. Chemical structures of metabolites recommended as screening targets for liquid 
chromatography-based urine screenings. 
Figure 3. Obtained standard addition calibration curves after addition of 0, 2, 4, 6, 8, or 10 ng/mL 
4-CEC, ephylone, NEH, and 4F-PHP to authentic human plasma after unknown dose and time of 
consumption. Analyte concentration is plotted versus peak area ratios of analyte and internal 
standard (trimipramine‐d3). 
Figure 4. Metabolic stability of 4-CEC (A), ephylone (B), NEH (C), and 5F-PHP (D) in 
incubations with pooled human liver microsomes (pHLM). Incubation time is plotted versus the 
natural logarithm of the peak area ratios of the analyte and the internal standard (IS). Points indicate 




Table 1. General involvement of monooxygenases in the formation of the given 4-CEC, 
ephylone, NEH, and 4F-PHP metabolites. Pooled human liver microsomes (pHLM) 
incubations were used as positive control. Metabolite IDs correspond to Table S1. CYP, 
cytochrome P450; FMO, flavin-containing monooxygenase, +, detected; -, not detected 
 
Parent compound CYP FMO3 pHLM 
Metabolite ID 1A2 2A6 2B6 2C8 2C9 2C19 2D6 2E1 3A4 3A5   
4-CEC             
M1 (N-deethyl-) + - + - - + - - - - - + 
M3 (dihydro-) - - - - - - - - - - - + 
M4 (hydroxylamine) + - - - - - - - + - + + 
Ephylone             
M10 (N-deethyl-) - - + - - + - - + - - + 
M15 (demethylenyl-) + - - - - + + - - - - + 
M18 (dihydro-) - - - - - - - - - - - + 
M20 (hydroxy-) - - - - - - - - + - - + 
M21 (hydroxylamine) - - - - - - - - + - + + 
NEH             
M29 (N-deethyl-) + - - - - + - - - - - + 
M31 (dihydro-) - - - - - - - - - - - + 
M33 (hydroxy-) + - - - - - - - - - - + 
M34 (hydroxy-) + - - - - - - - - - - + 
4F-PHP             
M41 (N,N-dealkyl-) + - + - - + - - + - - + 
M42 (dihydro-) - - - - - - - - - - - + 
M44 (oxo-) + - + - - - - - + - - + 
M45 (hydroxy-) + - - - - + - - - - - + 
M46 (hydroxy-) + - - - - + - - - - - + 






Table 2. Metabolic stability of 4-CEC, ephylone, NEH, and 4F-PHP in pooled human liver 
microsomes (pHLM) incubations expressed as in vitro half-life (t1/2) and calculated 
microsomal intrinsic clearance (CLint, micr) and intrinsic clearance (CLint). 
 
Compound t1/2, min CLint, micr, mL× min-1×mg-1 CLint, mL× min-1×kg-1 
4-CEC 105 0.0066 5.7 
Ephylone 96 0.0072 6.2 
NEH 85 0.0082 7.0 
4F-PHP 38 0.0182 15.7 
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Table S1. 4-CEC, ephylone, NEH, 4F-PHP, and their phase I and II metabolites identified in 
authentic human biosamples or pS9 incubations by means of LC-HRMS/MS together with the 
used ionization mode, precursor ion (PI) mass recorded in MS1, characteristic fragment ions 
(FI) in MS2, relative intensities in MS2, calculated exact masses, elemental compositions, 
deviation of the measured from the calculated masses, and retention times (RT). Metabolites 
were sorted by increasing mass and RT. ESI+, positive electrospray ionization mode; ESI-, 
negative electrospray ionization mode 
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- ESI + PI at m/z 212.0837 
FI at m/z 194.0732 
FI at m/z 166.0417 
FI at m/z 159.1043 
FI at m/z 144.0808 
FI at m/z 139.0309 






























M1 N-Deethylation ESI + PI at m/z 184.0519 
FI at m/z 167.0258 
FI at m/z 166.0417 
FI at m/z 139.0307 
FI at m/z 131.0729 


























M2 N-Deethylation + 
reduction 
ESI + PI at m/z 186.0675 
FI at m/z 168.0566 
FI at m/z 151.0301 
FI at m/z 133.0880 






















M3 Reduction ESI + PI at m/z 214.0990 
FI at m/z 196.0885 
FI at m/z 168.0571 
FI at m/z 151.0307 
FI at m/z 133.0886 


























M4 N-Oxygenation ESI + PI at m/z 228.0783 
FI at m/z 210.0678 
FI at m/z 175.0991 
FI at m/z 138.9945 






















M5 Carboxylation ESI + PI at m/z 242.0590 
FI at m/z 224.0462 
FI at m/z 196.0517 
FI at m/z 178.0410 
FI at m/z 168.0569 
































PI at m/z 270.0523 
FI at m/z 252.0419 
FI at m/z 210.0315 




























FI at m/z 167.0256 
FI at m/z 166.0416 
FI at m/z 139.0307 
FI at m/z 131.0728 
FI at m/z 103.0545 
PI at m/z 268.0369 
FI at m/z 224.0473 
FI at m/z 206.0369 
























































PI at m/z 284.0675 
FI at m/z 266.0573 
FI at m/z 248.0470 
FI at m/z 220.0518 
FI at m/z 184.0522 
FI at m/z 167.0258 
FI at m/z 166.0417 
FI at m/z 139.0307 
FI at m/z 131.0729 
FI at m/z 103.0545 
PI at m/z 282.0537 
FI at m/z 264.0431 
FI at m/z 220.0527 


















































































PI at m/z 298.0830 
FI at m/z 280.0729 
FI at m/z 262.0622 
FI at m/z 234.0677 
FI at m/z 184.0522 
FI at m/z 167.0255 
FI at m/z 166.0416 
FI at m/z 139.0307 
FI at m/z 131.0728 
FI at m/z 103.0545 
PI at m/z 296.0684 
FI at m/z 278.0588 
FI at m/z 234.0683 




































































M9 Reduction + 
glucuronidation 
ESI + PI at m/z 390.1296 
FI at m/z 214.0982 
FI at m/z 196.0879 
FI at m/z 168.0567 
FI at m/z 151.0303 































- ESI + PI at m/z 250.1435 
FI at m/z 232.1328 
FI at m/z 202.1225 
FI at m/z 175.0752 
FI at m/z 135.0440 


























M10 N-Deethylation ESI + PI at m/z 222.1122 
FI at m/z 204.1018 
FI at m/z 174.0913 
FI at m/z 146.0962 
FI at m/z 135.0440 






























ESI + PI at m/z 224.1271 
FI at m/z 206.1165 
FI at m/z 164.0697 
FI at m/z 150.0543 






















M12 N-Deethylation + ESI + PI at m/z 224.1272 2 224.1281 C12H18O3N -4.02 3.19 
reduction 
diastereomer 1 
FI at m/z 206.1167 
FI at m/z 174.0906 
FI at m/z 151.0383 
FI at m/z 146.0957 





















M13 N-Deethylation + 
reduction 
diastereomer 2 
ESI + PI at m/z 224.1270 
FI at m/z 206.1165 
FI at m/z 174.0906 
FI at m/z 151.0384 
FI at m/z 146.0957 






























ESI + PI at m/z 224.1270 
FI at m/z 206.1164 
FI at m/z 164.0698 
FI at m/z 150.0543 






















M15 Demethylenation ESI + PI at m/z 238.1433 
FI at m/z 220.1330 
FI at m/z 202.1225 
FI at m/z 177.0782 
FI at m/z 123.0441 





























ESI + PI at m/z 252.1591 
FI at m/z 234.1484 
FI at m/z 202.1224 
FI at m/z 175.0751 
FI at m/z 151.0389 





























ESI + PI at m/z 252.1589 
FI at m/z 234.1486 
FI at m/z 202.1225 
FI at m/z 175.0752 
FI at m/z 151.0390 




























ESI + PI at m/z 252.1604 
FI at m/z 234.1484 
FI at m/z 191.0937 
FI at m/z 149.0596 
























ESI + PI at m/z 252.1589 
FI at m/z 234.1479 
FI at m/z 191.0932 
FI at m/z 149.0591 






















M20 Hydroxylation ESI + PI at m/z 266.1384 
FI at m/z 248.1279 
FI at m/z 230.1176 
FI at m/z 206.0810 
FI at m/z 176.0706 


























M21 N-Oxygenation ESI + PI at m/z 266.1383 
FI at m/z 248.1274 
FI at m/z 176.0701 
FI at m/z 149.0233 
FI at m/z 121.0285 





























ESI + PI at m/z 318.0999 
FI at m/z 238.1437 
FI at m/z 220.1333 
FI at m/z 202.1224 


























ESI + PI at m/z 318.1004 
FI at m/z 238.1438 
FI at m/z 220.1333 
FI at m/z 202.1225 
FI at m/z 123.0444 



























+ methylation + 
sulfation 
ESI + PI at m/z 332.1154 
FI at m/z 252.1591 
FI at m/z 234.1486 
FI at m/z 202.1225 

























ESI + PI at m/z 414.1740 
FI at m/z 238.1425 
FI at m/z 220.1320 
FI at m/z 202.1216 
FI at m/z 123.0437 





























ESI + PI at m/z 414.1753 
FI at m/z 238.1434 
FI at m/z 220.1330 
FI at m/z 202.1225 
FI at m/z 123.0440 



























+ methylation + 
glucuronidation 
isomer 1 
ESI + PI at m/z 428.1910 
FI at m/z 252.1590 
FI at m/z 234.1485 
FI at m/z 202.1225 























+ methylation + 
glucuronidation 
isomer 2 
ESI + PI at m/z 428.1915 
FI at m/z 252.1591 
FI at m/z 234.1485 
FI at m/z 202.1224 


























- ESI + PI at m/z 220.1691 
FI at m/z 202.1587 
FI at m/z 175.1116 
FI at m/z 146.0962 
FI at m/z 118.0653 


























M29 N-Deethylation ESI + PI at m/z 192.1380 
FI at m/z 175.1116 
FI at m/z 174.1275 
FI at m/z 118.0653 






















M30 N-Deethylation + 
reduction 
ESI + PI at m/z 194.1540 
FI at m/z 176.1432 
FI at m/z 120.0809 


















M31 Reduction ESI + PI at m/z 222.1851 
FI at m/z 204.1745 
FI at m/z 176.1432 
FI at m/z 147.1040 






















M32 N-Deethylation + 
N-acetylation 
ESI + PI at m/z 234.1496 
FI at m/z 192.1380 
FI at m/z 175.1117 
FI at m/z 174.1275 
FI at m/z 118.0653 


























M33 Hydroxylation ESI + PI at m/z 236.1635 100 236.1645 C14H22O2N -4.23 3.70 
isomer 1 FI at m/z 218.1528 
FI at m/z 200.1425 
FI at m/z 173.0954 
FI at m/z 158.0958 
FI at m/z 105.0334 



























ESI + PI at m/z 236.1649 
FI at m/z 218.1537 
FI at m/z 191.1065 
FI at m/z 162.0912 






















M35 Reduction + 
hydroxylation 
ESI + PI at m/z 238.1791 
FI at m/z 220.1695 
FI at m/z 202.1581 
FI at m/z 175.1109 
FI at m/z 160.1114 
FI at m/z 105.0339 






























M36 Carboxylation ESI + PI at m/z 250.1435 
FI at m/z 232.1332 
FI at m/z 214.1227 
FI at m/z 202.1229 
FI at m/z 158.1176 


























M37 Reduction + 
glucuronidation 
diastereomer 1 
ESI + PI at m/z 398.2171 
FI at m/z 222.1848 
FI at m/z 204.1744 
FI at m/z 147.1040 






















M38 Reduction + 
glucuronidation 
diastereomer 2 
ESI + PI at m/z 398.2165 
FI at m/z 222.1855 
FI at m/z 204.1745 
FI at m/z 147.1042 






















M39 Hydroxylation + 
glucuronidation 
isomer 1 
ESI + PI at m/z 412.1969 
FI at m/z 236.1642 
FI at m/z 218.1536 
FI at m/z 191.1064 
FI at m/z 162.0912 


























M40 Hydroxylation + 
glucuronidation 
isomer 2 
ESI + PI at m/z 412.1949 
FI at m/z 236.1633 
FI at m/z 218.1530 
FI at m/z 200.1425 
FI at m/z 173.0957 
FI at m/z 158.0958 
FI at m/z 105.0336 






































- ESI + PI at m/z 264.1755 
FI at m/z 193.1021 
FI at m/z 140.1432 
FI at m/z 123.0242 
FI at m/z 109.0451 


























M41 N,N-Dealkylation ESI+ PI at m/z 210.1291 
FI at m/z 193.1022 
FI at m/z 192.1180 
FI at m/z 136.0556 
FI at m/z 123.0242 


























M42 Reduction ESI + PI at m/z 266.1910 29 266.1915 C16H25ONF -1.88 5.29 
FI at m/z 248.1807 
FI at m/z 191.1103 
FI at m/z 109.0451 



















ESI + PI at m/z 278.1538 
FI at m/z 193.1014 
FI at m/z 123.0237 
FI at m/z 109.0447 
























ESI + PI at m/z 278.1539 
FI at m/z 193.1015 
FI at m/z 154.1218 
FI at m/z 123.0237 
FI at m/z 109.0447 




























ESI + PI at m/z 280.1695 
FI at m/z 262.1592 
FI at m/z 204.1174 
FI at m/z 191.0857 
FI at m/z 156.1377 
FI at m/z 123.0237 
FI at m/z 109.0446 




































ESI + PI at m/z 280.1693 
FI at m/z 262.1588 
FI at m/z 204.1172 
FI at m/z 191.0860 
FI at m/z 156.1376 
FI at m/z 123.0236 
FI at m/z 109.0447 




































ESI + PI at m/z 280.1703 
FI at m/z 262.1599 
FI at m/z 234.1653 
FI at m/z 193.1022 
FI at m/z 156.1382 
FI at m/z 123.0242 
FI at m/z 109.0451 


































M48 Reduction + 
glucuronidation 
diastereomer 1 
ESI + PI at m/z 442.2214 
FI at m/z 266.1902 
FI at m/z 248.1797 
FI at m/z 191.1094 
FI at m/z 109.0446 


























M49 Reduction + 
glucuronidation 
diastereomer 2 
ESI + PI at m/z 442.2217 
FI at m/z 266.1904 
FI at m/z 248.1795 
FI at m/z 191.1095 
FI at m/z 109.0446 


























M50 Hydroxylation + 
glucuronidation 
isomer 1 
ESI + PI at m/z 456.2007 
FI at m/z 280.1698 
FI at m/z 262.1594 
FI at m/z 204.1179 
FI at m/z 191.0858 
FI at m/z 123.0236 
FI at m/z 109.0448 


































M51 Hydroxylation + 
glucuronidation 
ESI + PI at m/z 456.2019 










isomer 2 FI at m/z 262.1601 
FI at m/z 234.1663 
FI at m/z 193.1030 
FI at m/z 156.1382 
FI at m/z 123.0242 
FI at m/z 109.0452 































Table S2. Absolute peak areas of 4-CEC, ephylone, NEH, 4F-PHP, and their phase I and II 
metabolites in MS1 (ESI +) derived from analyses of authentic human biosamples and pS9 
incubations by LC-HRMS/MS. Plasma sample was diluted 1:4 and urine sample concentrated 
1:2 during sample preparation. The three largest peak areas of each compound and matrix are 
given in bold. Metabolites IDs correspond to Table S1. n.d., not detected 
 
Metabolite ID Metabolic 
reaction 
Human biosamples pS9 incubations 




- 1.28E+06 4.83E+08 3.30E+09 1.77E+09 




1.10E+06 5.67E+08 1.06E+05 4.30E+05 
M3 Reduction 3.61E+07 3.43E+09 2.45E+08 1.66E+08 
M4 N-Oxygenation n.d. n.d. 1.28E+07 1.19E+07 
M5 Carboxylation n.d. 2.38E+06 n.d. n.d. 
M6 N-Deethylation 
+ malonylation 
n.d. 1.63E+06 n.d. n.d. 
M7 N-Deethylation 
+ succinylation 
n.d. 1.86E+08 n.d. n.d. 
M8 N-Deethylation 
+ glutarylation 
n.d. 1.64E+07 n.d. n.d. 
M9 Reduction + 
glucuronidation 




- 7.37E+06 8.35E+08 6.91E+09 3.98E+09 




















n.d. 3.07E+07 n.d. n.d. 








1.82E+05 7.24E+07 1.26E+08 8.07E+07 
M18 Reduction 
diastereomer 1 
3.18E+05 5.69E+07 4.90E+07 2.87E+07 
M19 Reduction n.d. 6.56E+07 n.d. n.d. 
diastereomer 2 
M20 Hydroxylation n.d. 3.68E+06 4.84E+05 1.18E+06 








n.d. 4.38E+06 3.68E+05 8.81E+05 
M24 Demethylenation 
+ methylation + 
sulfation 










2.47E+06 2.98E+08 3.10E+06 2.05E+06 
M27 Demethylenation 
+ methylation + 
glucuronidation 
isomer 1 
1.46E+06 2.46E+08 1.90E+07 4.04E+07 
M28 Demethylenation 
+ methylation + 
glucuronidation 
isomer 2 
8.15E+05 1.76E+08 1.06E+07 1.12E+07 
NEH (parent 
compound) 
- 8.86E+05 1.16E+08 4.45E+09 2.29E +09 
M29 N-Deethylation 7.71E+05 7.29E+07 1.74E+08 2.40E+08 
M30 N-Deethylation 
+ reduction 
6.17E+05 6.18E+07 1.33E+07 9.38E+06 
M31 Reduction 1.65E+05 5.28E+07 2.23E+08 1.33E+08 
M32 N-Deethylation 
+ N-acetylation 
n.d. n.d. 1.36E+06 1.31E+06 
M33 Hydroxylation 
isomer 1 
6.56E+05 2.02E+08 4.61E+07 6.79E+07 
M34 Hydroxylation 
isomer 2 
n.d. 3.83E+06 9.25E+06 8.33E+06 
M35 Reduction + 
hydroxylation 
n.d. 3.10E+07 n.d. n.d. 
M36 Carboxylation n.d. 3.91E+07 n.d. 3.23E+05 
M37 Reduction + 
glucuronidation 
diastereomer 1 
n.d. 3.54E+07 n.d. 1.27E+05 






M39 Hydroxylation + 
glucuronidation 
isomer 1 
n.d. 1.43E+06 n.d. 3.53E+05 
M40 Hydroxylation + 
glucuronidation 
isomer 2 




- 1.16E+06 5.41E+07 7.47E+09 4.71E+09 
M41 N-Dealkylation n.d. 3.05E+06 4.11E+06 5.01E+06 
M42 Reduction 3.23E+06 4.17E+07 6.55E+08 4.92E+08 
M43 Carbonylation 
isomer 1 
9.62E+05 7.29E+07 n.d. n.d. 
M44 Carbonylation 
isomer 2 
2.76E+05 6.68E+07 5.15E+07 5.10E+07 
M45 Hydroxylation 
isomer 1 
n.d. 4.45E+06 8.01E+06 1.59E+07 
M46 Hydroxylation 
isomer 2 
n.d. 6.53E+06 5.66E+06 1.08E+07 
M47 Hydroxylation 
isomer 3 
n.d. n.d. 6.78E+07 1.11E+08 
M48 Reduction + 
glucuronidation 
diastereomer 1 
n.d. 7.57E+06 n.d. n.d. 
M49 Reduction + 
glucuronidation 
diastereomer 2 
n.d. 8.71E+07 2.08E+05 3.12E+05 
M50 Hydroxylation + 
glucuronidation 
isomer 1 
n.d. 2.79E+06 n.d. n.d. 
M51 Hydroxylation + 
glucuronidation 
isomer 2 
n.d. 1.51E+07 8.17E+05 1.93E+06 
 
  
Table S3. Targets identified in authentic human urine by means of GC-MS. Metabolites IDs 




Target Precursor ion 
mass, m/z 




4-CEC AC 253 72, 111, 114, 139 1920 
M2 N-Deethyl dihydro 4-CEC 2AC 269 72, 111, 114, 141 1995 
M3 Dihydro 4-CEC 2AC  297 86, 111, 141 2100 
Parent 
compound 
Ephylone AC 291 100, 121, 142, 149 2275 
M11/14 N-Deethyl-demethylenyl-
methyl ephylone AC  
265 72, 114, 151 2230 
M11/14 N-Deethyl-demethylenyl-
methyl ephylone 2AC 
307 72, 114, 151, 193, 265 2300 
M16/17 Demethylenyl-methyl ephylone 
AC 
293 100, 123, 142, 151 2265 
M16/17 Demethylenyl-methyl ephylone 
isomer 1 2AC 
335 100, 123, 142, 151 2355 
M16/17 Demethylenyl-methyl ephylone 
isomer 2 2AC 
335 100, 123, 142, 151 2395 
Parent 
compound 
NEH AC 261 77, 105, 114, 156 2030 
 
 
